Tagged with IBSA,

Switzerland From humble beginnings in southern Switzerland to crossing the USD 1 billion revenue mark, IBSA has quietly redefined what it means to grow a pharmaceutical company, without fanfare, without mega-mergers, and without compromising its values. In this interview, Chief Commercial Officer & Chairman of the Executive Committee Luca Crippa unpacks…

Italy While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit of innovation. On the contrary, the Italian life science scene is increasingly strong when it comes to behind-the-scenes, incremental innovation.…

USA A Tale of Two Americas The US stands as the biopharma innovation champion of the world, a global leader on nearly all R&D indices related to investment and innovation. It also holds a tremendous amount of clout, representing half the world’s healthcare market, and the US healthcare industry itself is…

USA Three US country managers for European pharma mid-caps explain the challenges in setting up an American affiliate, as well as how best to capitalise on the abundant opportunities in the world’s biggest pharma market.   For Jorge Alderete, president Americas & SVP commercial operations at Danish firm ALK, “Market access…

USA Aldo Donati, CEO for Swiss firm IBSA in the USA, discusses the challenges for European mid-caps in expanding to the US market and his portfolio strategy for ensuring future successes for IBSA USA.   In the global economy we are operating in, the US market cannot be ignored and if…

Hungary As general manager of the Hungarian affiliate of Swiss firm IBSA, Anna Wienner has proven herself to be a motivated pharma leader with particular expertise in reshaping and building organizations. Joining the company in 2015, Wienner took on her new position with the task of restructuring the stagnating affiliate. This…

Hungary In 2016, Hungary transitioned from a second-tier member to a full member of the EU. As Judit Bidló, deputy director general of pricing and reimbursement for Hungary’s National Institute of Health Insurance Fund Management (NEAK), explains, this has already had a significant impact on patient access to innovative new products.…

Hungary Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to offer her expert insights into key trends impacting the Hungarian healthcare ecosystem in areas such as in vitro fertilization, market…

Switzerland In view of the manifold hurdles encountered when attempting to raise capital, Switzerland’s medium capitalized entities and SMEs have grown adept at punching well above their weight. After the giants, Roche and Novartis, some of the larger companies in the Swiss pharma sector like Ferring and IBSA are privately held,…

Poland Leonardo Maffioli, senior marketing and commercial manager of the fertility and endocrinology division of IBSA, discusses the story of IBSA Poland and the potential of the Polish market for the company. Furthermore, he highlights the market challenges of the country, especially for fertility treatments during a period of a conservative…

Switzerland The southern Swiss canton of Ticino does not have the life science reputation of Basel, Zurich or Geneva, but benefits from an open business environment, strategic location, and a thriving network of pharmaceutical SMEs. “Ticino is really a perfect example of the excellence of Swiss SMEs in the pharma industry, as…

Switzerland As the largest privately owned pharmaceutical company in Switzerland, IBSA remains committed to continuing to invest and manufacture in Switzerland. Head of Swiss Business Operations Maleša Ulrico Sidjanski, MSc ETH, discusses the company’s current priorities, values, and upcoming investments.   What other mid-sized multinational pharmaceutical companies present in over 80…